A pioneering phase 2 trial was randomized for the application of IONIS-AGT-LRx (n = 17) or placebo (n = 8) in 25 patients with controlled hypertension on two antihypertensive medications (ACE inhibitors or angiotensin receptor blockers with beta-blockers, calcium channel blockers, or diuretics), as we have reinforced in the introduction section. The gene discussed is ACE; the disease is Hypertension.